|Page (1) of 1 - 10/06/17||email article||print page|
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.(October 06, 2017)
HOPKINTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two presentations at the annual American Association for the Study of Liver Disease (AASLD) conference (The Liver Meeting®) being held in Washington, D.C. on October 20-24, 2017. The first is an oral presentation entitled: “SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from Cohort 1 of the ACHIEVE trial,” and the second is a late-breaker poster presentation entitled: “Novel anti-viral activity of SB 9200, a RIG-I agonist; results from Cohort 1 of the ACHIEVE trial.”
“SB 9200 is a novel and exciting potential oral therapy with promising antiviral activity, and we are excited to see Professors Yuen and Locarnini, leaders in the field of clinical Hepatology and Virology, present data at this prestigious conference from the first low dose cohort of the ACHIEVE trial showing promising results of SB 9200 in patients with hepatitis B,” said Nezam Afdhal, M.D., D.Sc., Chief Medical Officer, Spring Bank Pharmaceuticals.
The annual AASLD conference will highlight the latest liver diseases research and discuss treatment outcomes with physicians, researchers and healthcare practitioners involved in the science and practice of hepatology. The abstracts will be presented at the conference as follows: